| Literature DB >> 30009275 |
Gretchen A Brenes1,2, Jasmin Divers3, Michael E Miller3, Suzanne C Danhauer2.
Abstract
BACKGROUND: Worry is a common problem among older adults. Cognitive-behavioral therapy is the most studied nonpharmacological intervention and it has demonstrated efficacy in reducing late-life worry and anxiety. Although the evidence-base is smaller, yoga has been shown to reduce anxiety and stress. However, little is known about the relative effectiveness of these two nonpharmacological interventions. Further, the impact of patient preference on outcomes is unknown.Purpose: The purpose to this study is to compare the effectiveness of cognitive-behavioral therapy (CBT) with yoga for improving late-life worry, anxiety, and sleep. We will also examine the effects of preference and selection on outcomes, adherence, and attrition.Entities:
Keywords: Cognitive-behavioral therapy; Late-life anxiety; Randomized preference trial; Yoga
Year: 2018 PMID: 30009275 PMCID: PMC6042466 DOI: 10.1016/j.conctc.2018.05.002
Source DB: PubMed Journal: Contemp Clin Trials Commun ISSN: 2451-8654
Fig. 1Randomization and assessment schedule.
CBT = Cognitive-behavioral therapy.
Description and timing of study measures.
| Week 0 | Week 6 | Week 11 | Week 37 | Description | ||
|---|---|---|---|---|---|---|
| Primary Outcome Measure | ||||||
| Penn State Worry Questionnaire-Abbreviated (PSWQ-A) [ | X | X | X | X | 8-item measure of frequency/intensity of worry; most commonly used worry measure. Strong psychometrics [ | |
| Secondary Outcome Measures | ||||||
| PROMIS Anxiety [ | X | X | X | X | Included in PROMIS 29 (described below). | |
| Insomnia Sleep Index [ | X | X | X | X | 7-item self-report measure of type and severity of insomnia symptoms | |
| Additional Outcome Measures | ||||||
| PROMIS 29 [ | X | X | X | 29-item self-report measure with 4 items each for the following: physical function, anxiety, depression, fatigue, sleep, social function, pain interference; 1 item for average pain intensity. Physical and social function domains assess current function; items for other domains reference past 7 days. | ||
| PROMIS Depression [ | X | X | X | Included in PROMIS 29 (described above). | ||
| PROMIS Physical Function [ | X | X | X | Self-report measure of current capability for physical activities. Will use only 4 unique items (not already in the PROMIS-29). | ||
| GAD-7 [ | X | X | X | Self-report measure of DSM-IV GAD symptoms. Validated for use in general population [ | ||
| Demographic and Health-Related Information | ||||||
| Demographics and health | X | Self-report age, education (years), gender, race, income. Self-rated health (0–100). | ||||
| Charlson Comorbidity Index [ | X | X | X | Creates weighted index to account for number/seriousness of comorbidities. | ||
| Medical Services Utilization/Medication Use | ||||||
| Cornell Services Index [ | X | X | X | Structured interview; assesses services used; aggregated into outpatient psychiatric or psychological services, outpatient medical services, professional support services, and intensive services. | ||
| Medication use [ | X | X | X | Participant provides name/dosage of all prescription medications in past month. | ||
| Process Measures | ||||||
| Expectancy Rating Scale [ | X (after 1st session for CBT group) | Assesses beliefs in how logical the treatment seems, confidence in undergoing treatment/recommending to others, and expectations for success. Used in anxiety treatment studies with older adults [ | ||||
| Client Satisfaction Questionnaire [ | X | Assesses satisfaction with treatment. Adequate reliability with older adults [ | ||||
| Working Alliance Inventory, Client and Therapist [ | X | Assesses therapist-patient working alliance. Strong psychometrics [ | ||||
| Intervention adherence | X | The percentage of completed sessions (max = 10 CBT; max = 20 yoga). | ||||
| Other Measures | ||||||
| Patient treatment preferences | X | Preferred treatment/strength of preference. For preference trial only. | ||||
Achievable power relative to detectable effect size and longitudinal correlation, with N = 250 individuals randomized into the random trial.
| Standardized effect size | Correlation between baseline and follow-up PSWQ-A score | |||||
|---|---|---|---|---|---|---|
| 0.3 | 0.35 | 0.4 | 0.45 | 0.5 | 0.55 | |
| 0.15 | 0.42 | 0.43 | 0.45 | 0.47 | 0.49 | 0.52 |
| 0.20 | 0.65 | 0.66 | 0.68 | 0.71 | 0.73 | 0.76 |
| 0.25 | 0.83 | 0.85 | 0.86 | 0.88 | 0.90 | 0.92 |
| 0.30 | 0.94 | 0.95 | 0.95 | 0.96 | 0.97 | 0.98 |
| 0.35 | 0.98 | 0.99 | 0.99 | 0.99 | 0.99 | 1 |
Achievable power for detectable preference and selection effect sizes, with N = 500 individuals assuming an equal preference for treatment (φ = 0.5).
| Preference effect size | Selection effect size | |||||||
|---|---|---|---|---|---|---|---|---|
| 0.2 | 0.25 | 0.3 | 0.35 | 0.4 | 0.45 | 0.5 | 0.55 | |
| 0.20 | (0.71, 0.83) | (0.71, 0.76) | (0.71, 0.68) | (0.71, 0.58) | (0.71, 0.52) | (0.71, 0.62) | (0.71, 0.71) | (0.71, 0.79) |
| 0.25 | (0.84, 0.79) | (0.84, 0.69) | (0.84, 0.58) | (0.84, 0.53) | (0.84, 0.65) | (0.84, 0.75) | (0.83, 0.83) | (0.83, 0.90) |
| 0.30 | (0.91, 0.75) | (0.91, 0.63) | (0.91, 0.51) | (0.91, 0.62) | (0.91, 0.74) | (0.90, 0.83) | (0.90, 0.90) | (0.90, 0.95) |
| 0.35 | (0.94, 0.71) | (0.94, 0.59) | (0.94, 0.55) | (0.94, 0.69) | (0.94, 0.80) | (0.94, 0.88) | (0.94, 0.94) | (0.94, 0.97) |
| 0.40 | (0.96, 0.69) | (0.96, 0.55) | (0.96, 0.59) | (0.96, 0.73) | (0.96, 0.84) | (0.96, 0.91) | (0.96, 0.96) | (0.96, 0.98) |
| 0.45 | (0.97, 0.68) | (0.97, 0.53) | (0.97, 0.62) | (0.97, 0.75) | (0.97, 0.85) | (0.97, 0.92) | (0.96, 0.96) | (0.96, 0.99) |
| 0.50 | (0.97, 0.67) | (0.97, 0.53) | (0.97, 0.62) | (0.97, 0.75) | (0.97, 0.86) | (0.97, 0.93) | (0.97, 0.97) | (0.96, 0.99) |
| 0.55 | (0.97, 0.68) | (0.97, 0.54) | (0.97, 0.61) | (0.97, 0.74) | (0.96, 0.85) | (0.96, 0.92) | (0.96, 0.96) | (0.96, 0.98) |
Note that power for the preference effect (rows) is listed first in parentheses, followed by the power for the selection effect (columns).